

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,025,964 B1
APPLICATION NO. : 09/308027
DATED : April 11, 2006
INVENTOR(S) : Akinori Kume et al.

Page 1 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title Page, Item 56 References Cited Section - OTHER PUBLICATIONS, line 4: "Janpanese" should be --Japanese--.

On the Title Page, Item 57

In the Abstract, lines 1-3: "A peptide-based immunotherapeutic agent effective for every allergy patient is provided. A reagent for typing HLA class II molecules of the patient to be used in selecting a peptide-based immunotherapeutic agent effective for every allergy patient is also provided."

should read as follows:

--Peptide-based immunotherapeutic agents effective for each individual allergy patient are provided. Reagents for typing HLA class II molecules of patients to be used in selecting peptide-based immunotherapeutic agents effective for each individual allergy patient are also provided.--.

Col. 5, second paragraph, line 16, "challenge" should be --challenged--.

Col. 6, line 6, "to" should be --of--.

Col. 6, line 7, "allergy" should be--allergy.--.

Col. 6, line 7, "caused by antigen peptides presented by HLA-DPB1*0501.

HLA-DPB1*0501 is frequently present in patients suffering from Cryptomeria pollen allergy induced by Cry j 1 and Cry j 2, and antigen peptides presented by different HLA class II molecules (DR.DQ or DP) (Japanese Patent Application No. Hei 8-70702)."

should read as follows:

--These multiple-epitope peptides comprise antigen peptides presented by different HLA class II molecules (DR, DQ or DP),and antigen peptides that are derived from both Cry j 1 and Cry j 2 and which are presented by HLA-DPB1*0501 (Japanese Patent Application No. Hei 8-80702). HLA-DPB1*0501 exists at a high frequency in patients suffering from cryptomeria pollen allergy.--

Col. 6, line 4, after "provided" please add --, for example,--.

Col. 6, line 5, "multiple" should be --multi--.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,025,964 B1
APPLICATION NO. : 09/308027
DATED : April 11, 2006
INVENTOR(S) : Akinori Kume et al.

Page 2 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 7, line 1, "there is a bias in the use of HLA class II (at the locus level) molecules that is determined by the antigen."

should read as follows:

--, depending on the antigen type, there is a bias towards restriction molecules at the HLA class II locus level, and that this defines immune reactions.--.

Col. 8, line 11, "Moreover, if T-cell response can be found in a subject (an allergic-response-positive patient), the type of the subject's HLA class II molecules restricting the antigen peptides that induced the T-cell response can be identified as the HLA class II type endowing susceptibility to said allergen in the subject."

should read as follows:

--For subjects showing a T cell response (allergy response-positive patients), the type of HLA class II restriction molecule for the antigen peptide that induces the T cell response can be identified as the subjects' HLA class II type.--.

Col. 8, line 65, "expression of a polypeptide with a peptide composed of"
should read as follows: --expressing, as a polypeptide, a peptide with--.

Col. 9, line 14, "shows the overlapping peptides of Cry j 1 containing epitopes recognized by patient's T-cells"

should read as follows: --shows Cry j 1 overlapping peptide sequences and the patients' T-cell epitope sites.--

Col. 9, line 18, "shows the overlapping peptides of Cry j 2 containing epitopes recognized by patient's T-cells"

should read as follows: --shows Cry j 2 overlapping peptides and the patients' T-cell epitope sites.--.

Col. 9, line 39, "shows the immune responses of CB6F1 mouse to Cry j 2 when the antigen peptide p186-200 of Cry j 2 was administered to the mouse."

should read as follows; --shows the immune response of CB6F1 mice to Cry j 2 when the antigen peptide p236-250 of Cry j 2 was administered to the mice.--.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,025,964 B1
APPLICATION NO. : 09/308027
DATED : April 11, 2006
INVENTOR(S) : Akinori Kume et al.

Page 3 of 3

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 11, line 1, "The number of T-cell epitope sites of Cry j 1 recognized by each patient was 9.8 ± 3.0 on average and ranged from 4 = 15 epitopes."

should read as follows:

--Identification of T-cell epitope sites using T-cell lines recognizing Cry j 1 revealed that the number of T-cell epitope sites recognized by each patient was 9.8 ± 3.0 on average and ranged from 4 = 15 epitopes.--

Col. 12, line 36, "Restriction molecules of each LHA class II type of T-cell clones whose restriction molecules were identified at the locus level can be identified by using, as antigen-presenting cells, mouse L-cells transformed with the DR gene and B-cell lines that are homozygous at the DQ or DP loci."

should read as follows:

--Restriction molecules of each HLA class II type of T-cell clones whose restriction molecules were identified at the locus level can be identified by using as antigen-presenting cells, mouse L-cells transformed with the DR gene and B-cell lines having the same DQ or DP haplotype.--

Col. 13, line 7, "(Medojenics)" should be --(MedGenics)--.

Col. 55, Claim 1, line 48, "0501" should be --1501--.


Col. 56, Claim 2, line 47, "0501" should be --1501--.

This certificate supersedes Certificate of Correction issued December 12, 2006.

and April 3, 2007,

Signed and Sealed this

Third Day of April, 2007



Akinori Kume
United States Patent and Trademark Office

Note
Note